MiR-155 not only regulates tumor growth and metastasis [27] but also modulates the anti-tumor immune response by influencing the PD-1/PD-L1 axis [28], suggesting its potential clinical utility as a candidate biomarker of disease progression and treatment response. This evidence concerns the gene PDCD1 and neoplasm.